Shanghai Bao Pharmaceuticals Co., Ltd. (HKG:2659)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
17.97
-0.06 (-0.33%)
Jun 18, 2026, 4:08 PM HKT

Shanghai Bao Pharmaceuticals Company Description

Shanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainland China.

The company uses synthetic biology technology to develop and deliver recombinant biologic drugs. Its products include KJ017, a recombinant human hyaluronidase for subcutaneous drug delivery; KJ103, a recombinant immunoglobulin G (IgG)-degrading enzyme for IgG-mediated autoimmune diseases; and SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH CTP) for assisted reproduction.

The company also develops KJ101, a recombinant human chymotrypsin developed through synthetic biology that is in Phase 2 clinical trials; KJ015, a bispecific anti HER2 antibody; BJ007, a subcutaneous formulation of ceftriaxone sodium for the treatment of bacterial infections; BJ009, a first generation cephalosporin antibiotic for treating bacterial infections, including of the skin, bones, joints, reproductive organs, blood, heart valves, respiratory tract, biliary tract, and urinary tract; and SJ04, a recombinant human chorionic gonadotropin (hCG) that can be used in assisted reproductive procedures to accelerate follicle maturation and induce ovulation.

These product candidates are in Phase 1 clinical trials. In addition, it is developing BJ045, a subcutaneously administered anti CD20 antibody; BJ047, a subcutaneously administered anti CD154 antibody; BJ008, a subcutaneous formulation of cefoperazone sodium–sulbactam sodium to treat bacterial infections; and BJ044, a serine protease inhibitor with broad anti inflammatory properties.

These product candidates are in the preclinical stage. Further, the company licenses its intellectual property and other deliverables and provides technical services.

Shanghai Bao Pharmaceuticals Co., Ltd. was founded in 2019 and is based in Shanghai, China.

Shanghai Bao Pharmaceuticals Co., Ltd.
CountryChina
Founded2019
IndustryBiotechnology
SectorHealthcare
Employees354
CEOWang Zheng

Contact Details

Address:
No. 28 Luoxin Road
Shanghai
China
Phone86 21 5669 6602
Websitebaopharma.com

Stock Details

Ticker Symbol2659
ExchangeHong Kong Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyCNY
ISIN NumberCNE100007B92
SIC Code2836

Key Executives

NamePosition
Wang ZhengCo-Founder, Chief Executive Officer and Executive Director
Dr. Liu YanjunCo-Founder and Executive Chairman
Li CuiChief Financial Officer, Joint Company Secretary and Executive Director
Haiman FongJoint Company Secretary